Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative Phase II clinical trial between its recombinant protein COVID-19 vaccine, ReCOV ("ReCOV") and Pfizer's mRNA...
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") in mainland China. Ensifentrine is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4")...
Minderoo Foundation and Illumina Commit $40M to Apply Advanced Genomics to Marine Conservation
New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods SAN DIEGO, Aug. 19, 2022 /PRNewswire/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will...
uLab Systems™ ranked in top 20% of the Inc. 5000 annual list of the fastest growing companies in America
MEMPHIS, Tenn., Aug. 18, 2022 /PRNewswire/ -- Inc. has recognized uLab Systems, the only orthodontic company ranked in the Health Products industry category, for the explosive growth of 832% from 2018 to 2021, thus assigning a rank within the top 20% of their annual Inc. 5000 list. The Inc. list is...
Ping An Health posts revenue of RMB2,828 million in the first half of 2022
Gross margin improves to 27.3%Cumulative paying users reaches over 40 million HONG KONG and SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or "Ping An Health"; Stock Code: 1833.HK), announced its 2022 interim results. Since the deepening of Strategy 2.0 Continuum, the Company has steadily implemented its differentiated "managed care...
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in China, 1 in global, 13 indications approved and 4 New Drug Applications (NDAs) now accepted by the National Medical Products Administration (NMPA), focusing...
WeTrade Group Inc. Ready to kick-off a Strategic Partnership with Zhixun Bio through WeTrade’s SaaS platform and its the Internet of Things (IoT)
BEIJING, Aug. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company is in an advanced discussion with Zhixun Biotechnology Limited("Zhixun"), a company who specializes in production of medical sterilization products. WeTrade and Zhixun...
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has approved the clinical trial application for GFH312 in a randomized, double-blinded, placebo-controlled phase II monotherapy study. The trial will be conducted in patients with peripheral artery disease and with intermittent claudication at...
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for the development and commercialization of its androgen...
Zylox-Tonbridge maintains strong revenue and gross profit growth, including gross margin improvement driven by its platform-based strategy in 1H22
HANGZHOU, China, Aug. 18, 2022 /PRNewswire/ -- On August 15, Zylox-Tonbridge (2190.HK, "the Company") released its 2022 interim results. The Company's revenue increased 113.7% YoY to RMB 1.53 billion in the first six months of 2022. The revenue of neurovascular interventional products business increased 160.1% YoY to RMB 1.12 billion, and the revenue of peripheral-vascular interventional products business increased...
